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Abstract. The study was aimed to determine the platinum-resistance biomarkers in patients 
with ovarian cancer. The expression of ABCA1 is higher in platinum-resistant cases of ovarian 
cancer. The most pronounced relationship exists between the values of survivin expression, local 
activity of nitric oxide, the expression of glutathione dependent enzymes, the content of 
catecholamines in erythrocytes, and the expression of ABCA1 transporter 
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Introduction. According to the International Agency for Research on Cancer, more than 165,000 
new cases of ovarian cancer are reported annually in the world and more than 100,000 women die from 
malignant ovarian tumors. According to mortality rates, ovarian cancer ranking 5th among the causes of 
death from all tumors in women. The mortality of patients with ovarian cancer in the first year after 
diagnosis is 35 % [1, 2]. Overall five-year survival rate of patients with ovarian cancer does not exceed 35-
40 % [3]. These circumstances are due to the asymptomatic flow of ovarian cancerRH in the early stages, 
which leads to late diagnosis of the disease, when radical surgical intervention is not possible. 
The problem of ovarian cancer has a huge medical and social significance. According to the 
aggregated data of population cancer registries of European countries, one-year survival rate of 
patients with MS is 63 %, three years - 41 %, five years - 35 %. In the last decade in Europe, the 
increase in the five-year survival rate of patients with malignant tumors of the ovaries by 3 % (from 
32 to 35 %), and in the United States - by 4 % (from 35 to 39 %) is due not so much to improving 
diagnosis, but due to implementing effective platinum-based chemotherapy in the treatment of 
disseminated forms of ovarian cancer and germinogenic tumors [4, 5]. 
To date, the "gold standard" for treatment of the IB-IIIC stages is surgical intervention with 
the subsequent rate of post-operative chemotherapy. At the same time the drug of choice is platinum 
preparations. The mechanism of action of platinum derivatives is associated with DNA damage, 
resulting in the formation of so-called cisplatin-DNA adducts, which, in turn, block replication, 
transcription and suppress the proliferation of malignantly transformed cells [4]. 
Resistance to platinum preparations is considered as a multifactorial phenomenon, which is 
due to a decrease in intracellular cytostatic accumulation, increased activity of glutathione 
detoxification systems and metallothioneins, disorders of the repair system of damaged DNA etc. [6-8] 
Depending on the progression of the disease, it is customary to distinguish between the 
following types of ovarian cancer: platinum-refractory (progressing during first-line chemotherapy 
with the inclusion of platinum preparations), platinum-resistant (progressing within 6 months after the 
completion of first-line chemotherapy with the inclusion of platinum preparations) and platinum-
susceptible (progressing more than 6 months after the completion of first-line chemotherapy) [6]. 
Purpose of the study: to determine the platinum-resistance biomarkers in patients with ovarian cancer. 
Material and methods. The research was performed not on the basis of the regional oncology 
clinic (Odessa, Ukraine). 29 platinum-resistant patients with verified ovary cancer of IIIB-IIIC stages 
were examined, who received 6 courses of adjuvant chemotherapy with platinum preparations 
(cisplatin 75-100 mg/m
2
 intravenously with hydration and forced diuresis every 3 weeks) in the 
postoperative period. As control, 26 patients with non-recurrence of the disease performed for 
6 months post-treatment observation (platinum-susceptible tumors) were observed. 
The criteria for the relapse registration, according to FIGO recommendations, were the levels 
of markers of CA-125, NE4 and CT data of the pelvic organs, abdominal cavity and retroperitoneum, 
as well as the patient's objective examination [9]. 
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All patients analyzed the possible risk factors for resistance to platinum at the level of the 
body and tissues, including analysis of clinical and anamnestic characteristics, risk factors for ovarian 
cancer, analysis of potential predictors of platinum resistance. Expression of endothelial growth factor, 
vascular endothelial growth factor receptors, cyclin D, cyclin E, p53, pAkt, Bcl-2, sarvivin, ABC 
transporter A1 in tumor tissue by immunohistochemical method [11] was studied. Additionally, local 
activity of nitric oxide, expression of catecholamines in erythrocytes and intracellular sulfur activity in 
tumor tissue [12] were analyzed. 
A comparative analysis of the data was carried out using Fischer's exact criterion and the 
besserial correlation analysis. Statistical analysis of data was carried out using the Statistica 10.0 (Dell 
StatSoft Inc.) program [13]. 
Research results. It was found that in platinum-susceptible patients, VEGF expression in 
tumor tissue was 55 (27; 122) pg/mg, while platinum-resistant 95 (45-147) pg/ml (p> 0.05). The 
expression of VEGFR-1 in platinum-resistant patients was 2.4 (1.9-3.2) pg/ml, and platinum-
sensitive 2.5 (2.0-3.0) pg/ml. In contrast, the expression of VEGFR-2 was 170 (120-222) pg/ml and 
165 (150-190) pg/ml, respectively (p> 0.05). The content of pAkt was 0.2 (0.1- 0,3) pg/ml, and in 
platinum-sensitive ones - 0,5 (0,3-0,8) pg/ml. The content of Bcl-2 was 45 (25-135) pg/ml and 
117 (35-225) pg/ml, respectively. The protein content of p53 in tumor tissue of platinum-sensitive patients 
was 4.5 ± 0.7 U/ml, while in the tissue of platinum-resistant tumors - 3.9 ± 0.6 U/ml only (p>0,05). 
It was also found that in platinum-resistant cases, a positive reaction to the content of 
survivine was determined both in the cytoplasm and within the nucleus. Instead, in platinum-
susceptible patients, in most cases (92.3 %) only a positive response was recorded in the cytoplasm. 
For platinum-resistant cases of ovarian cancer, the expression of NOS (an average of 
1.2±0.2 points) and a high content of intracellular sulfur (3.8±0.2 points) were characteristic declining, 
whereas in platinum-sensitive cases, respectively, 3.2±0, 4 and 2.7±0.3 points (p <0.05). 
The content of catecholamines in erythrocytes of patients with ovarian cancer was 
significantly higher in platinum-resistant cases (up to 3.0 ± 0.03 granules/RBC), whereas in platinum-
sensitive cases this figure was 2.6 ± 0.02 granules/RBC. 
Positive reaction to cyclin D content was found in 4 (13.8 %) platinum-resistant patients, 
while platinum-susceptible ones were found in 5 (19.2 %) patients. Positive response to cyclin E was 
determined in 6 (20.7 %) in platinum-resistant patients and in 4 (15.4 %) platinum-susceptible 
patients. Statistically significant differences were not found for these indices (p> 0.05). 
Positive reaction to ABCA1 was detected in 9 (31.0 %) platinum-resistant and 5 (19.2 %) 
platinum-susceptible ones (p<0,05). In the course of the correlation analysis, it was found that the 
most pronounced relationship exists between the values of survivin expression, local activity of nitric 
oxide, the expression of glutathione dependent enzymes, the content of catecholamines in 
erythrocytes, and the expression of ABCA1 transporter (Table 1). 
 
Table 1. Correlation between the biomarkers of platinum resistance 
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VEGF 0,12 0,24 -0,08 -0,11 0,16 0,25 0,27 -0,18 -0,09 0,15 0,18 0,26 
VEGFR-1  0,22 0,10 -0,09 0,07 0,19 0,21 0,12 0,05 0,11 0,14 0,12 
VGFR-2   0,19 -0,08 -0,12 0,15 0,27 0,06 -0,11 0,09 0,12 0,24 
pAkt    0,13 -0,02 0,19 0,15 0,09 -0,07 0,18 0,22 0,13 
Bcl-2     0,18 0,27 0,13 -0,14 0,17 -0,08 -0,19 0,16 
p53      0,23 0,06 -0,17 0,09 0,17 -0,15 0,05 
Surv.       0,39 -0,33 0,35 0,28 0,29 0,54 
NOS        0,42 0,39 0,30 0,28 0,59 
S         0,33 -0,27 -0,28 0,53 
KCH          0,31 0,33 0,45 
C.D           0,62 0,41 
C.E            0,43 
 
The evidence suggests that there are common mechanisms for influencing the platinum resistance 
processes and the appropriateness of control of the level of expression of survivin, local activity of nitric 
